

Our Ref: FOI ID 48163

23 May 2018

southportandformbyccg.foi@nhs.net

NHS Southport & Formby CCG
5 Curzon Road
Southport
PR8 6PL

Tel : 0151 317 8456

Email: southportandformby.ccg@nhs.net

Re: Freedom of Information Request

Please find below the response to your recent Freedom of Information request regarding CCG decisions with patient care and the structure of NHS Southport and Formby CCG.

Request/Response:

1. What criteria does the CCG use to select which inhalers should be prescribed for Asthma and COPD?
2. How does the CCG compare the cost-effectiveness , efficacy, safety and patient usability of different inhalers when selecting which COPD and Asthma inhalers should be included on its local guidance?
3. Over the past three years, has the CCG introduced a planned programme of care which resulted in the medicines optimisation team, contractors or GP practices proactively reviewing patients and aligning their COPD and/or Asthma inhalers to alternative options?
4. Please list the alternative asthma and COPD inhalers that were introduced by the CCGs medicines optimisation team, contractors or GP practices during any planned programme of care that proactively reviewed the use of asthma and/or COPD inhalers over the past 3 years .
5. Over the past three years, has the CCG used a QIPP scheme to introduce a planned programme of care which resulted in the medicines optimisation team, contractors or GP practices proactively reviewing patients and aligning their COPD and/or Asthma inhalers to alternative options?
6. Please list the alternative asthma and COPD inhalers that were introduced by the CCGs medicines optimisation team, contractors or GP practices when using a QIPP scheme to introduce a planned programme of care that proactively reviewed the use of asthma and/ or COPD inhalers over the past 3 years?

For Questions 1 – 6

The CCG is a member of the Pan Mersey Area Prescribing Committee (APC). Recommendations from Pan Mersey APC are considered by the CCG and ratified if in agreement. Full details of the respiratory formulary chapter and guidance ratified by the CCG (denoting by a box at the top of statements) can be found at <http://formulary.panmerseyapc.nhs.uk/chaptersSub.asp?FormularySectionID=3>

During 17/18 the CCG medicines management team members working with GP practices reviewed COPD patients to optimise their inhalers in line with Pan Mersey APC formulary choices. This involved reviewing patients on Spiriva handihaler and changing them where appropriate to alternative long acting muscarinic antagonists including the Spiriva Respimat, Incruse Ellipta and the Braltus Zonda inhaler.

Patients prescribed Seretide MDI and accuhaler have been opportunistically switched to Fostair and the Relvar Ellipta inhaler in line with Pan Mersey guidelines.

The work will continue into 18/19 where we will also optimise inhalers for asthma in line with Pan Maersey APC formulary choices. Initially Seretide monitored dosage inhaler devices will be reviewed and changed to Airflusal monitored dosage inhaler where appropriate.

7. I would also like to make a request for the full name, contact number and contact email for the following roles listed below within your CCG;

Roles:

Chief Executive Officer

Fiona Taylor – Fiona.taylor@southseftonccg.nhs.uk

Chief Financial Officer

Martin McDowell – Martin.McDowell@southseftonccg.nhs.uk

Medicines Management Lead

Susanne Lynch – Susanne.lynch@southseftonccg.nhs.uk